Skip Navigation



Annals of Oncology Advance Access published online on February 16, 2007
Annals of Oncology, doi:10.1093/annonc/mdl496
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/4/679    most recent
mdl496v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Evens, A.
Right arrow Articles by Gordon, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Evens, A.
Right arrow Articles by Gordon, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma

AM Evens1, JK Altman1, BB Mittal2, N Hou3, A Rademaker3, D Patton1, L Kaminer1, S Williams1, S Duffey1, D Variakojis4, S Singhal1, MS Tallman1, J Mehta1, JN Winter1 and LI Gordon1,*

1 Division of Hematology/Oncology, Hematopoietic Stem Cell Transplant Program and Lymphoma Program, Feinberg School of Medicine, Northwestern University and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
2 Department of Radiation Oncology
3 Department of Preventive Medicine
4 Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

* Correspondence to: Dr L. I. Gordon, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, 676 North St Clair, Suite 850, Chicago, IL 60611, USA. Tel: +1-312-695-4517, Fax: +1-312-695-6189, E-mail: l-gordon{at}northwestern.edu.

Background: The standard approach to treatment of relapsed/refractory Hodgkin's lymphoma (HL) is high-dose chemotherapy conditioning followed by autologous hematopoietic stem-cell transplantation (aHSCT). We report the results of a prospective phase I/II clinical trial of accelerated hyperfractionated total lymphoid irradiation (TLI) immediately followed by high-dose chemotherapy for relapsed/refractory HL.

Patients and methods: Forty-eight patients underwent aHSCT with either sequential TLI/chemotherapy (n = 32) or chemotherapy-alone conditioning (n = 16), based on prior radiation exposure. The first 22 patients enrolled on trial received escalating doses of etoposide (1600–2100 mg/m2) with high-dose carboplatin and cyclophosphamide.

Results: No dose-limiting toxicity was seen and TLI/chemotherapy was well tolerated. The 5-year event-free survival (EFS) estimate for all patients was 44% with overall survival (OS) of 48%. Five-year EFS and OS for the TLI/chemotherapy group was 63% and 61%, respectively, compared with 6% and 27%, respectively, for the chemotherapy-alone group (P < 0.0001 and P = 0.04, respectively). Patients with primary induction failure HL who received TLI/chemotherapy had 5-year EFS and OS rate of 83%. The 100-day treatment-related mortality was 4.2% and two secondary cancers were seen. Significant factors predicting survival by multivariate analysis included TLI/chemotherapy conditioning and B symptoms at relapse.

Conclusions: Sequential TLI/chemotherapy conditioning for relapsed/refractory HL is safe and associated with excellent long-term survival rates.

autologous transplantation, Hodgkin's lymphoma, outcomes, prognosis, therapy, total lymphoid irradiation

Received for publication September 26, 2006. Revision received November 21, 2006. Accepted for publication December 12, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.